As reported elsewhere [24], our laboratory generated and characterised several cellular models of trastuzumab-resistant HER2-positive breast cancer lines, covering, albeit to a limited extent, a range of genetic heterogeneity. The gene discussed is ERBB2; the disease is breast cancer.